Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
There’s limited access to California’s cheap insulin, Eli Lilly’s cracking down on black market retatrutide, and new biotech Khartis Therapeutics emerges with $95 million.
Some rather buff fellows at my gym were comparing abdomens today, raving about the bodysculpting wonders of all that illicit “reta.” I imagine they won’t be too pleased about the Lilly news.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
